正常血清降钙素和大肿块甲状腺髓样癌的研究进展

摘要/Abstract

摘要：

甲状腺髓样癌（medullary thyroid carcinoma, MTC）具有侵袭性强、较早出现淋巴结转移及远处转移的特点。在甲状腺肿瘤中,MTC侵袭程度仅次于未分化癌。血清降钙素是检测MTC最敏感的肿瘤标志物,并与肿瘤大小相关。然而,当肿瘤直径>1 cm时,部分MTC病人血清降钙素处于正常范围,给诊断带来困难。本文综述肿瘤直径>1 cm、血清降钙素正常的MTC研究进展。

中图分类号:

R736.1

李瑞, 刘卓然综述, 严佶祺审校. 正常血清降钙素和大肿块甲状腺髓样癌的研究进展[J]. 外科理论与实践, 2022, 27(03): 271-275.

LI Rui, LIU Zhuoran, YAN Jiqi. Progress of study on medullary thyroid carcinoma with serum calcitonin-negative and large mass[J]. Journal of Surgery Concepts & Practice, 2022, 27(03): 271-275.

图/表1

表1

肿瘤直径>1 cm CNMTC病人的临床资料（n=21）

参考文献	性别	年龄（岁）	肿瘤直径（cm）	随访时间	预后	降钙素（免疫组织化学）	术后降钙素	术后癌胚抗原	细针穿刺	转染期间重排基因
Samà等^{[ 4 ]}	男	60	3.8	10年	无复发	弱阳性	未升高	未升高	/	阴性
	男	53	1.2	3年	无复发	/	未升高	未升高	/	阳性
	男	62	4.5	1年	无复发	弱阳性	未升高	未升高	/	阴性
Sobol等^{[ 11 ]}	女	82	2.0	23个月	6个月后转移,23个月后死亡	阴性	未升高	未升高	/	/
Redding等^{[ 12 ]}	女	31	4.5	43个月	无复发	强阳性	未升高	未升高	恶性	/
Bockhorn等^{[ 13 ]}	女	50	2.0	5年	无复发	弱阳性	/	/	/	阴性
Sand等^{[ 14 ]}	女	73	>4.0	6周	死于肺转移和脑转移	弱阳性	/	/	/	/
Giovanella等^{[ 15 ]}	女	43	3.6	2年	无复发	强阳性	未升高	未升高	恶性	/
Dora等^{[ 16 ]}	男	43	1.7	/	/	强阳性	/	/	恶性	阴性
Alapat等^{[ 17 ]}	女	16	3.0	20个月	无复发	强阳性	未升高	未升高	MTC	/
Frank-Raue等^{[ 18 ]}	男	70	8.0	2.25年	伴肺转移	弱阳性	未升高	未升高	/	阴性
	女	50	2.0	12.5年	10年后复发	弱阳性	未升高	升高	MTC	阳性
	男	47	3.0	1.5年	无复发	强阳性	未升高	未升高	/	阴性
	女	53	4.5	1.75年	伴远处转移	强阳性	未升高	未升高	MTC	阳性
	男	45	1.8	1.75年	死于肺转移	弱阳性	升高	未升高	/	阳性
	女	45	5.5	3年	死于肺转移	强阳性	未升高	未升高	/	阳性
Brutsaert等^{[ 19 ]}	女	39	2.6	/	/	强阳性	/	/	恶性	阴性
Murphy等^{[ 22 ]}	女	24	3.5	3年	无复发	阴性	未升高	未升高	/	阴性
Jingzhu等^{[ 23 ]}	男	66	7.0	2个月	死于局部复发	强阳性	/	/	/	/
	女	65	1.48	15个月	死于肝、脑、肺转移	弱阳性	/	/	/	/
Montgomery等^{[ 25 ]}	男	45	2.3	/	/	阴性	/	/	NET	/

表1

参考文献42

[1]	Viola D, Elisei R. Management of medullary thyroid cancer[J]. Endocrinol Metab Clin North Am, 2019, 48(1):285-301. doi:10.1016/j.ecl.2018.11.006 URL
[2]	Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6):567-610. doi:10.1089/thy.2014.0335 URL
[3]	Ceolin L, Duval MADS, Benini AF, et al. Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives[J]. Endocr Relat Cancer, 2019, 26(9):R499-R518.
[4]	Samà MT, Rossetto Giaccherino R, Gallo M, et al. Clinical challenges with calcitonin-negative medullary thyroid carcinoma[J]. J Cancer Res Clin Oncol, 2016, 142(9):2023-2029. doi:10.1007/s00432-016-2169-5 URL
[5]	Liu Y, Yuan L, Yang D, et al. Serum calcitonin negative mixed medullary-follicular carcinoma initially diagnosed as medullary thyroid carcinoma by fine-needle aspiration cytology: a case report and review of the literatures[J]. Diagn Cytopathol, 2018, 46(8):690-693. doi:10.1002/dc.23924 URL
[6]	Kartal Baykan E, Erdoan M. Basal and pentagastrin-stimulated calcitonin cut-off values in diagnosis of preoperative medullary thyroid cancer[J]. Turk J Med Sci, 2021, 51(2):650-656. doi:10.3906/sag-2003-182pmid:33128357
[7]	Filimon S, Payne RJ, Black MJ, et al. Calcitonin secretory index and unsuspected nodal disease in medullary thyroid carcinoma[J]. Endocr Pract, 2018, 24(5):460-467. doi:10.4158/EP-2017-0236pmid:29847167
[8]	王宇, 田文, 嵇庆海, 等. 甲状腺髓样癌诊断与治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(9):1012-1020.
[9]	Haddad RI, Nasr C, Bischoff L, et al. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018[J]. J Natl Compr Canc Netw, 2018, 16(12):1429-1440. doi:10.6004/jnccn.2018.0089 URL
[10]	Allelein S, Ehlers M, Morneau C, et al. Measurement of basal serum calcitonin for the diagnosis of medullary thyroid cancer[J]. Horm Metab Res, 2018, 50(1):23-28. doi:10.1055/s-0043-122237 URL
[11]	Sobol RE, Memoli V, Deftos LJ. Hormone-negative, chromogranin A-positive endocrine tumors[J]. N Engl J Med, 1989, 320(7):444-447. doi:10.1056/NEJM198902163200707 URL
[12]	Redding AH, Levine SN, Fowler MR. Normal preoperative calcitonin levels do not always exclude medullary thyroid carcinoma in patients with large palpable thyroid masses[J]. Thyroid, 2000, 10(10):919-922. pmid:11081258
[13]	Bockhorn M, Frilling A, Rewerk S, et al. Lack of eleva-ted serum carcinoembryonic antigen and calcitonin in medullary thyroid carcinoma[J]. Thyroid, 2004, 14(6):468-470. doi:10.1089/105072504323150813 URL
[14]	Sand M, Gelos M, Sand D, et al. Serum calcitonin negative medullary thyroid carcinoma[J]. World J Surg Oncol, 2006, 4:97. doi:10.1186/1477-7819-4-97 URL
[15]	Giovanella L, Crippa S, Cariani L. Serum calcitonin-negative medullary thyroid carcinoma: role of CgA and CEA as complementary markers[J]. Int J Biol Markers, 2008, 23(2):129-131. doi:10.1177/172460080802300212 URL
[16]	Dora JM, Canalli MH, Capp C, et al. Normal perioperative serum calcitonin levels in patients with advanced medullary thyroid carcinoma: case report and review of the literature[J]. Thyroid, 2008, 18(8):895-899. doi:10.1089/thy.2007.0231 URL
[17]	Alapat DV, Ain KB, Sloan DA, et al. Disparity between tissue and serum calcitonin and carcinoembryonic antigen in a patient with medullary thyroid carcinoma[J]. Endocrine, 2011, 39(2):148-152. doi:10.1007/s12020-010-9433-2pmid:21243446
[18]	Frank-Raue K, Machens A, Leidig-Bruckner G, et al. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma[J]. Thyroid, 2013, 23(3):294-300. doi:10.1089/thy.2012.0236pmid:22946486
[19]	Brutsaert EF, Gersten AJ, Tassler AB, et al. Medullary thyroid cancer with undetectable serum calcitonin[J]. J Clin Endocrinol Metab, 2015, 100(2):337-341. doi:10.1210/jc.2014-3095pmid:25490273
[20]	Zhou Q, Yue S, Cheng Y, et al. Clinical and pathological analysis of 19 cases of medullary thyroid carcinoma without an increase in calcitonin[J]. Exp Toxicol Pathol, 2017, 69(8):575-579. doi:10.1016/j.etp.2017.05.003 URL
[21]	Cipri C, Vescini F, Torresan F, et al. An unusual case of medullary thyroid carcinoma and a revision of current li-terature[J]. Endocr Metab Immune Disord Drug Targets, 2019, 19(2):226-229. doi:10.2174/1871530319666181220165350 URL
[22]	Murphy DC, Johnson SJ, Aspinall S. Calcitonin-negative medullary thyroid carcinoma: the “triple-negative” pheno-type[J]. Ann R Coll Surg Engl, 2020, 102(3):e63-e66.
[23]	Jingzhu Z, Xiangqian Z, Ming G, et al. Clinical challenges with calcitonin-negative medullary thyroid carcinoma: three case reports and a review of the literature[J]. Ann R Coll Surg Engl, 2022, 104(3):221-230.
[24]	Kim SJ, Yun HJ, Shin SJ, et al. Serum calcitonin-negative medullary thyroid carcinoma: a case series of 19 patients in a single center[J]. Front Endocrinol (Lausanne), 2021, 12:747704. doi:10.3389/fendo.2021.747704 URL
[25]	Montgomery G, Collins L, Coghlin C, et al. Calcitonin negative medullary thyroid cancer in ectopic thyroid tissue: a rare diagnosis in an unusual location[J]. BMJ Case Rep, 2020, 13(8):e236865. doi:10.1136/bcr-2020-236865 URL
[26]	Leboeuf R, Langlois MF, Martin M, et al. “Hook effect” in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature[J]. J Clin Endocrinol Metab, 2006, 91(2):361-364. doi:10.1210/jc.2005-1429 URL
[27]	Fernández-Ferreira R, De la Peña-López IR, Zamudio-Coronado KW, et al. Calcitonin-negative neuroendocrine carcinoma of the thyroid gland: case report and literature review[J]. Case Rep Oncol, 2021, 14(1):112-122. doi:10.1159/000510807pmid:33776692
[28]	Leboulleux S, Baudin E, Young J, et al. Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma[J]. Eur J Endocrinol, 1999, 140(3):187-191. doi:10.1530/eje.0.1400187pmid:10216512
[29]	Konstantinidis A, Stang M, Roman SA, et al. Surgical management of medullary thyroid carcinoma[J]. Updates Surg, 2017, 69(2):151-160. doi:10.1007/s13304-017-0443-ypmid:28409442
[30]	Hassan A, Siddique M, Riaz S, et al. Medullary thyroid carcinoma: prognostic variables and tumour markers affecting survival[J]. J Ayub Med Coll Abbottabad, 2018, 30(4):S627-S632.
[31]	Parmer M, Milan S, Torabi A. Calcitonin-negative neuroendocrine tumor of the thyroid[J]. Int J Surg Pathol, 2017, 25(2):191-194. doi:10.1177/1066896916670989pmid:27658647
[32]	Giovanella L, Garo ML, Ceriani L, et al. Procalcitonin as an alternative tumor marker of medullary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2021, 106(12):3634-3643. doi:10.1210/clinem/dgab564pmid:34382653
[33]	Karagiannis AK, Girio-Fragkoulakis C, Nakouti T. Procalcitonin: a new biomarker for medullary thyroid cancer? a systematic review[J]. Anticancer Res, 2016, 36(8):3803-3810. pmid:27466480
[34]	Vargas CVF, Ceolin L, Scheffel RS, et al. The tissue expression pattern of CA 19.9 is associated with oncological features in medullary thyroid carcinoma[J]. Endocrine, 2020, 70(3):544-551. doi:10.1007/s12020-020-02377-3 URL
[35]	Elisei R, Lorusso L, Piaggi P, et al. Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer[J]. Eur J Endocrinol, 2015, 173(3):297-304. doi:10.1530/EJE-15-0304 URL
[36]	Liu MJ, Liu ZF, Hou YY, et al. Ultrasonographic characteristics of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma[J]. Oncotarget, 2017, 8(16):27520-27528. doi:10.18632/oncotarget.15897 URL
[37]	Tripathy S, Aggrawal S, Subudhi K, et al. Calcitonin-negative neuroendocrine tumor of the thyroid on 68Ga DOTANOC PET-CT[J]. Clin Nucl Med, 2019, 44(9):e546-e547.
[38]	Naswa N, Sharma P, Suman Kc S, et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT[J]. Nucl Med Commun, 2012, 33(7):766-774. doi:10.1097/MNM.0b013e3283541157 URL
[39]	Trimboli P, Giovanella L, Crescenzi A, et al. Medullary thyroid cancer diagnosis: an appraisal[J]. Head Neck, 2014, 36(8):1216-1223. doi:10.1002/hed.23449 URL
[40]	Trimboli P, Cremonini N, Ceriani L, et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study[J]. Clin Endocrinol (Oxf), 2014, 80(1):135-140. doi:10.1111/cen.12234 URL
[41]	Salvatore D, Santoro M, Schlumberger M. The importance of the RET gene in thyroid cancer and therapeutic implications[J]. Nat Rev Endocrinol, 2021, 17(5):296-306. doi:10.1038/s41574-021-00470-9pmid:33603219
[42]	Thomas CM, Asa SL, Ezzat S, et al. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines[J]. Curr Oncol, 2019, 26(5):338-344. doi:10.3747/co.26.5539pmid:31708652